venetoclax,quizartinib,decitabine
roche,daiichi sankyo,abbvie
['quizartinib', 'venetoclax', 'myeloid', 'leukemia']
venetoclax, quizartinib and decitabine resulted in a complete response of 78% in patients with relapsed or refractory flt3-mutated acute myeloid leukemia in a phase i/ii study. dr. musa yilmaz will present more data at #eha22: #endcancer
Driven by our mission to #EndCancer, MD Anderson is a leader in cancer care, research, education and training, and prevention. Appointments: 1-877-632-6789